News & Publications › Latest News  

Latest News

July 23, 2021
Brooklyn Immuno Reports Inducement Grants

July 19, 2021
Brooklyn ImmunoTherapeutics Completes Acquisition of Novellus Therapeutics

July 13, 2021
Brooklyn ImmunoTherapeutics Welcomes Jay Sial as Chief Administrative Officer

July 12, 2021
Brooklyn ImmunoTherapeutics to Present at the Access to Giving Virtual Investor Conference on July 15, 2021

July 6, 2021
Brooklyn ImmunoTherapeutics Reports Inducement Grants

June 14, 2021
Brooklyn ImmunoTherapeutics Executes Letter of Intent to Buy Novellus Therapeutics

June 9, 2021
Brooklyn ImmunoTherapeutics Set to Join Russell 3000 Index

June 7, 2021
Brooklyn ImmunoTherapeutics Welcomes Dr. Kevin A. D’Amour as Chief Scientific Officer

June 2, 2021
Brooklyn ImmunoTherapeutics Establishes Research and Development Center in Cambridge, Massachusetts

May 26, 2021
Brooklyn ImmunoTherapeutics CEO Howard J. Federoff Provides Roadmap for the Company’s Future During May 25, 2021 Shareholder Update Call

May 24, 2021
Brooklyn ImmunoTherapeutics Strengthens Investment in Licensed mRNA Technology Platform with $20M Financing

May 21, 2021
Michael Andreeff, M.D., Ph.D to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics, Inc.

May 18, 2021
Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call Tuesday May 25, 2021 at 4:30 PM ET

May 11, 2021
Brooklyn ImmunoTherapeutics Announces Publication of Results of IRX-2 Monotherapy in Early Stage Breast Cancer in Breast Cancer Research

May 7, 2021
Erich Mohr, Ph.D., to Join the Board of Directors of Brooklyn ImmunoTherapeuticsBrooklyn ImmunoTherapeutics Reports Inducement Grants

April 29, 2021
Brooklyn ImmunoTherapeutics Acquires License for mRNA Technology Platform to Develop Genetically Edited Cells to Treat Multiple Cancers, Blood and Other Disorders

April 26, 2021
Matthew During, M.D., Ph.D. to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics

April 19, 2021
Brooklyn ImmunoTherapeutics Reports Inducement Grants

April 16, 2021
Brooklyn ImmunoTherapeutics Pays $1 Million Towards Acquisition of License for mRNA Technology Platform to Develop Genetically Edited Cells for Multiple Cancers and Blood Disorders

April 15, 2021
Dennis H. Langer, M.D., J.D. to Join the Board of Directors of Brooklyn ImmunoTherapeutics, Inc.

April 6, 2021
Howard J. Federoff, MD, PhD Appointed Chief Executive Officer of Brooklyn ImmunoTherapeutics, Inc.

March 25, 2021
Brooklyn ImmunoTherapeutics Completes Reverse Merger with NTN Buzztime

February 09, 2021
Brooklyn ImmunoTherapeutics Announces Initiation of Phase 2 Trial of IRX-2 in Combination with Pembrolizumab and Chemotherapy in Triple Negative Breast Cancer

August 13, 2020
NTN Buzztime, Inc. and Brooklyn ImmunoTherapeutics LLC Enter into Definitive Merger Agreement

March 2, 2020
2020 Head and Neck Cancers Symposium: Immune Restorative Agent May Boost Immunotherapy Response in Advanced Head and Neck Cancer

June 3, 2019
Brooklyn ImmunoTherapeutics Announces Presentation of Ongoing Investigator Sponsored Trial of IRX-2 Regimen Combined with Nivolumab in Recurrent/Metastatic Solid Tumors

April 8, 2019
New clinical trials to investigate combination immunotherapy for treating advanced cancers

November 10, 2018
Brooklyn ImmunoTherapeutics Announces Presentation of Positive Results of IRX-2 Therapy in Resectable Breast Cancer and Head and Neck Cancer at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer

November 7, 2018
Brooklyn ImmunoTherapeutics Acquires IRX Therapeutics

November 7, 2018
Brooklyn ImmunoTherapeutics Announces Results of IRX-2 Therapy in Resectable Breast Cancer and Head and Neck Cancer Accepted for Oral Presentation at the 2018 Annual Meeting of the Society for Immunotherapy of Cancer